The Interplay of Antigen Affinity, Internalization, and Pharmacokinetics on CD44-Positive Tumor Targeting of Monoclonal Antibodies

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Monoclonal antibodies (mAbs) are promising for cancer therapy, targeting tumors and delivering drugs.
• Different mAbs targeting the same tumor-associated antigen (TAA) exhibit diverse biological and clinical behaviors.
• CD44, a cancer-associated cell-surface receptor and cancer stem cell marker, is a target for mAb-based cancer therapies.

Purpose of the Study:

• To investigate the characteristics of mAbs that influence tumor targeting efficacy.
• To evaluate a panel of CD44-specific mAb clones for their potential in cancer therapy.
• To determine the relationship between mAb properties (affinity, internalization) and in vivo tumor uptake.

Main Methods:

• Screening of CD44 mAb clones for cell-surface binding and antigen affinity.
• Assessment of mAb internalization by CD44-positive A549 cells in vitro.
• Evaluation of CD44-mediated tumor uptake and retention in A549 tumor-bearing mice models.
• Correlation analysis between mAb characteristics and tumor targeting performance.

Main Results:

• High-affinity CD44 mAbs demonstrated rapid binding and internalization in vitro.
• An intermediate-affinity CD44 mAb clone showed superior tumor uptake and retention in vivo compared to high-affinity clones.
• Systemic exposure of mAbs was identified as the strongest predictor of tumor targeting in A549 tumor-bearing mice.

Conclusions:

• mAb characteristics like antigen affinity and internalization rate do not solely dictate in vivo tumor targeting efficacy.
• Systemic exposure is a critical factor for successful tumor targeting with CD44 mAbs.
• These findings provide insights for optimizing mAb-based cancer therapeutics by considering systemic exposure alongside antigen-specific properties.